kabutan

PRISM BioLab Slips on Profit-Taking Despite Joint Presentation with Eisai on E7386 Preclinical Data◇

Tue Apr 7, 2026 9:22 am JST Catalyst

Shares of PRISM BioLab <206A> experienced volatile trading. After the market close on the 6th, the company announced that Eisai <4523> will present preclinical study results regarding the combination therapy of "E7386"?a compound co-developed by the two companies?and the anticancer drug "Lenvima." The study indicated that the combination of E7386 and Lenvima demonstrated stronger anti-angiogenic effects on tumor microvessels and higher antitumor activity compared to Lenvima monotherapy. While PRISM BioLab's stock opened higher on this positive news, it subsequently gave up its gains as profit-taking emerged. Eisai is currently conducting clinical trials for the E7386 and Lenvima combination therapy targeting advanced solid tumors, including endometrial cancer.

Related Articles